Thursday, August 16, 2018
 
 
Company News: Page (1) of 1 - 12/07/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Resverlogix Repays $68.8 Million Loan

(December 07, 2017)

CALGARY, Alberta, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has repaid, in full, its CAD$68.8 million Loan (the “Loan”). Upon repayment of the Loan, the Company has no outstanding long-term debt.

Mr. Donald McCaffrey, President and CEO commented, "Retiring the Loan in its entirety significantly strengthens Resverlogix’s financial position and increases our degrees of freedom as we move forward. We would like to thank Eastern Capital for its support in providing the letter of credit, which secured the Loan at a very favourable rate. This attractive financing permitted us to significantly advance the development of apabetalone (RVX-208), including the launch of the Phase 3 trial BETonMACE."

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx)

For further information please contact:

Investor Relations

Email: [email protected] Phone: 403-254-9252


Or visit our website: www.resverlogix.com


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   USDailyNews ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • Wearable Medical Devices Global Market Opportunities And Strategies To 2022
  • New Report Identifies Unique Challenges for LGBT Community Facing Alzheimer's and Other Dementias
  • The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease,
  • The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease

    Cancer
  • Biotest AG: Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time
  • Agenus Receives Second Milestone Payment from Merck
  • Colorado Pain Care Broadens Practice to Include Cancer Patient Treatment in Denver, CO and Surrounding Area
  • Citius Pharmaceuticals Successfully Raises $10 Million
  • ViewRay Announces Pricing of Public Offering of Common Stock
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines